M A Sahraian
Overview
Explore the profile of M A Sahraian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamout B, Al-Jumah M, Sahraian M, Almalik Y, Khaburi J, Shalaby N, et al.
Mult Scler Relat Disord
. 2024 Jan;
83:105435.
PMID: 38245998
With evolving diagnostic criteria and the advent of new oral and parenteral therapies for Multiple Sclerosis (MS), most current diagnostic and treatment algorithms need revision and updating. The diagnosis of...
2.
Kasbi N, Ghadiri F, Sahraian M, Nahayati M, Moghadasi A, Langroodi H, et al.
Acta Neurol Belg
. 2023 Sep;
124(1):205-212.
PMID: 37715074
Background: Ocrelizumab is a humanized antiCD20, thought to be a highly effective disease-modifying therapy (DMT). Its most frequent adverse effects are infusion-related reactions (IRRs). To reduce these reactions, the first...
3.
Ghadiri F, Eskandarieh S, Sahraian M, Azimi A, Moghadasi A
Rev Neurol (Paris)
. 2021 Nov;
178(3):249-252.
PMID: 34776261
Introduction: Neuromyelitis optica spectrum disorder (NMOSD) is a disabling autoimmune disease of the central nervous system that can start at ages of 50 or more, when it is called late-onset...
4.
Shahrezaee M, Keshtkari S, Moradi-Lakeh M, Abbasifard M, Alipour V, Amini S, et al.
Arch Osteoporos
. 2020 Jul;
15(1):103.
PMID: 32651719
Purpose: MSDs comprise most of the top causes of years lived with disability (YLDs) worldwide and are rapidly increasing in lower- and middle-income countries. Here, we present disability and mortality...
5.
Navardi S, Sahraian M, Moghadasi A
Rev Neurol (Paris)
. 2019 Nov;
176(4):289-290.
PMID: 31668286
No abstract available.
6.
Fereshtehnejad S, Vosoughi K, Heydarpour P, Sepanlou S, Farzadfar F, Tehrani-Banihashemi A, et al.
Eur J Neurol
. 2019 Apr;
26(10):1252-1265.
PMID: 31006162
Background And Purpose: The Eastern Mediterranean Region (EMR) is experiencing a demographic shift towards rapid aging at a time of political unrest. We aimed to estimate the burden of neurodegenerative...
7.
Heydarpour P, Manouchehrinia A, Beiki O, Mousavi S, Abdolalizadeh A, -Lakeh M, et al.
Acta Neurol Scand
. 2018 Mar;
138(1):62-69.
PMID: 29542102
Objectives: Multiple sclerosis (MS) is a chronic demyelinating disorder affecting young adults. Environmental factors and lifestyle behaviors are pivotal in MS pathophysiology. Smoking has been considered as an important risk...
8.
Rahmanzadeh R, Weber M, Bruck W, Navardi S, Sahraian M
Acta Neurol Scand
. 2018 Mar;
137(6):544-556.
PMID: 29512131
For decades, B cells were ignored in multiple sclerosis (MS) pathogenesis, and the disease was always regarded as a T cell-mediated disorder. Recent evidence shows that there is an antigen-driven...
9.
Rezazadeh M, Gharesouran J, Movafagh A, Taheri M, Darvish H, Emamalizadeh B, et al.
J Mol Neurosci
. 2015 Apr;
56(3):593-6.
PMID: 25823437
Primate-specific genes and regulatory mechanisms could provide insight into human brain functioning and disease. In a genome-scale analysis of the entire protein-coding genes listed in the GeneCards database, we have...
10.
Rezaee A, Azadi A, Houshmand M, Mahmoodi F, Purpak Z, Safaei S, et al.
Genet Mol Res
. 2013 Sep;
12(3):3551-4.
PMID: 24065688
Multiple sclerosis (MS) is an immunological inflammatory disease of the central nervous system. The pathogenesis of MS is incompletely understood, but various studies have suggested that mitochondrial dysfunction is associated...